CCCC
C4 Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$445.59M
P/E Ratio
—
EPS
$-1.10
Beta
2.93
52W High
$4.60
52W Low
$1.36
50-Day MA
$3.24
200-Day MA
$2.62
Dividend Yield
—
Profit Margin
-297.80%
Forward P/E
—
PEG Ratio
—
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $34.86M |
| Gross Profit (TTM) | $27.31M |
| EBITDA | $-101.20M |
| Operating Margin | -451.60% |
| Return on Equity | -48.30% |
| Return on Assets | -19.90% |
| Revenue/Share (TTM) | $0.36 |
| Book Value | $2.25 |
| Price-to-Book | 1.82 |
| Price-to-Sales (TTM) | 13.15 |
| EV/Revenue | 7.17 |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -15.00% |
| Shares Outstanding | $110.57M |
| Float | $83.64M |
| % Insiders | 1.13% |
| % Institutions | 85.11% |
Historical Volatility
HV 10-Day
87.36%
HV 20-Day
106.17%
HV 30-Day
99.07%
HV 60-Day
91.53%
HV Rank
48.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($13.33 target)
1
Strong Buy7
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026